Toinv - Hang in there, just a little more to go. As they said on slide 20 of the 11 March presentation, trial to continue until 250+ narrow MACE events have occurred. Top Line data will be announced after adjudication completion. Key subgroup analysis will also be released if available. 

Time lines could move as a result of healthier overall patients, better SOC drugs, better patient management by the clinics they are dealing with and of course less MACE events as a result of the great new drug apabetalone that they are testing in this trial. As BDAZ said in an earlier post the event rate drops after the first six months in the trial. The 10 to 15 events per month stated at the AGM was still within that six months of recruiting. After Sept was outside of that six month window.

Communications could have been better in the past however the addition of Paul Moon seems to have changed that. We have had an update on the number of events at least every month this year through slide decks presented at conferences that RVX has presented at.

Im hopeful they will meet the H1 Top Line date but won't be to disappointed if they don't. They always have the option of paying a little more to have the adjudication processed a little faster if required.

tada